InvestorsHub Logo
Followers 8
Posts 812
Boards Moderated 0
Alias Born 07/24/2016

Re: gi197845 post# 4574

Thursday, 12/01/2016 6:01:44 PM

Thursday, December 01, 2016 6:01:44 PM

Post# of 20617
Hi Gi197545

"FDA has until 12/31/17 for Fluticare review/approval/rejection, until it's considered late and being that the FDA is usually always late, it could take until 3/31/18 and by that time the market will be dominated by either flonase, or nasal issue will be cured by another big pharma."

I doubt it will be cured but the length of time to wait is obnoxious for sure.

Also, why would anyone buy these non RX products? Most people get an insurance company copay for an RX.

OTC medication is fairly common and it's possible for insurers to pay for some Rx's that are OTC though it's not often. Also, copays are rising significantly so I imagine it will continue to be a cheaper option than most. I would need to go look at what Rxs are and the general cost. I guarantee its a difference in price and more often than not it's tiered differently so insurers will likely force people to pay OOP.

How many unhorny women could really be out there anyway, that want zestra? A lot, look at who got elected. (Total slight at who is elected I know!)

Could an Alzheimer victim actually remember to by Recall Max? I assume it is geared more towards spouses and families. Since it's targeting a progressively worsening disease people will look for hope in any product said to help with symptoms.

"Thus far, I'm down 40+% on my INNV investment."

Dang, I would suggest if possible to average down. I am waiting for it to drop in the teens if I am to pick up more myself.

It's amazing to me that how slow and craptacular the FDA is!

It's been severely underfunded for years. Blame the GOP

https://www.washingtonpost.com/politics/house-republicans-vote-to-cut-funds-to-implement-food-safety-law/2011/06/16/AGMS82XH_story.html?utm_term=.8f8562d7bd61

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.